TrialThe Journal of clinical endocrinology and metabolism2026

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

Jan Wolf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.